Improved synthesis and anticancer activity of a potent neuronal nitric oxide synthase inhibitor

Bioorg Med Chem Lett. 2023 Jun 15:90:129329. doi: 10.1016/j.bmcl.2023.129329. Epub 2023 May 15.

Abstract

An improved synthesis of 4-methyl-7-(3-((methylamino)methyl)phenethyl)quinolin-2-amine (1) is reported. A scalable, rapid, and efficient methodology was developed to access this compound with an overall yield of 35%, which is 5.9-fold higher than the previous report. The key differences in the improved synthesis are a high yielding quinoline synthesis by a Knorr reaction, a copper-mediated Sonogashira coupling to the internal alkyne in excellent yield, and a crucial deprotection of the N-acetyl and N-Boc groups achieved under acidic conditions in a single step rather than a poor yielding quinoline N-oxide strategy, basic deprotection conditions, and low yielding copper-free conditions that were reported in the previous report. Compound 1, which previously was shown to inhibit IFN-γ-induced tumor growth in a human melanoma xenograft mouse model, was found to inhibit the growth of metastatic melanoma, glioblastoma, and hepatocellular carcinoma in vitro.

Keywords: Enzyme Inhibitor; Improved synthesis; Inhibition of cancers; Neuronal nitric oxide synthase.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Cells, Cultured
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Melanoma*
  • Mice
  • Nitric Oxide
  • Nitric Oxide Synthase Type I
  • Nitric Oxide Synthase*

Substances

  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type I
  • Enzyme Inhibitors
  • Nitric Oxide